

Jonathan W Friedberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3075390/publications.pdf>

Version: 2024-02-01

98
papers

2,356
citations

279798

23
h-index

214800

47
g-index

99
all docs

99
docs citations

99
times ranked

3242
citing authors

#	ARTICLE	IF	CITATIONS
1	Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496). <i>Journal of Clinical Oncology</i> , 2013, 31, 684-691.	1.6	256
2	US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. <i>Journal of Clinical Oncology</i> , 2016, 34, 2020-2027.	1.6	239
3	Outcomes of transformed follicular lymphoma in the modern era: a report from the National LymphoCare Study (NLCS). <i>Blood</i> , 2015, 126, 851-857.	1.4	161
4	In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma. <i>Cancer Discovery</i> , 2018, 8, 1258-1269.	9.4	136
5	Phase 2 study of idelalisib and entospletinib: pneumonitis limits combination therapy in relapsed refractory CLL and NHL. <i>Blood</i> , 2016, 127, 2411-2415.	1.4	131
6	Phase 2 study of frontline brentuximab vedotin monotherapy in Hodgkin lymphoma patients aged 60 years and older. <i>Blood</i> , 2015, 126, 2798-2804.	1.4	118
7	The Bruton tyrosine kinase inhibitor ibrutinib with chemoimmunotherapy in patients with chronic lymphocytic leukemia. <i>Blood</i> , 2015, 125, 2915-2922.	1.4	104
8	CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET. <i>Blood</i> , 2018, 132, 1013-1021.	1.4	90
9	Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. <i>Blood</i> , 2019, 134, 1238-1246.	1.4	86
10	Phase II study of a TLR9 agonist (1018 ISS) with rituximab in patients with relapsed or refractory follicular lymphoma. <i>British Journal of Haematology</i> , 2009, 146, 282-291.	2.5	75
11	Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001. <i>Journal of Clinical Oncology</i> , 2020, 38, 3003-3011.	1.6	75
12	A phase II trial to evaluate the efficacy of fostamatinib in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). <i>European Journal of Cancer</i> , 2016, 54, 11-17.	2.8	63
13	Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. <i>Blood Advances</i> , 2017, 1, 2600-2609.	5.2	62
14	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial. <i>Blood</i> , 2020, 135, 2224-2234.	1.4	62
15	Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research. <i>Journal of the National Cancer Institute</i> , 2016, 108, djw257.	6.3	56
16	Inhibition of COP9-signalosome (CSN) deneddylating activity and tumor growth of diffuse large B-cell lymphomas by doxycycline. <i>Oncotarget</i> , 2015, 6, 14796-14813.	1.8	42
17	New Strategies in Diffuse Large B-cell Lymphoma: Translating Findings from Gene Expression Analyses into Clinical Practice. <i>Clinical Cancer Research</i> , 2011, 17, 6112-6117.	7.0	37
18	Burkitt lymphoma- a rare but challenging lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2018, 31, 279-284.	1.7	37

#	ARTICLE	IF	CITATIONS
19	Hodgkin Lymphoma: Current Status and Clinical Trial Recommendations. Journal of the National Cancer Institute, 2017, 109, djw249.	6.3	31
20	Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1. Blood, 2016, 128, LBA-6-LBA-6.	1.4	30
21	Short term results of vaccination with adjuvanted recombinant varicella zoster glycoprotein E during initial BTK inhibitor therapy for CLL or lymphoplasmacytic lymphoma. Leukemia, 2021, 35, 1788-1791.	7.2	29
22	Phase I Study of the Investigational Aurora A Kinase Inhibitor Alisertib plus Rituximab or Rituximab/Vincristine in Relapsed/Refractory Aggressive B-cell Lymphoma. Clinical Cancer Research, 2018, 24, 6150-6159.	7.0	27
23	Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma. Clinical Cancer Research, 2019, 25, 1718-1726.	7.0	26
24	Recommendations for Clinical Trial Development in Follicular Lymphoma. Journal of the National Cancer Institute, 2017, 109, djw255.	6.3	23
25	R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG) Tj ETQq1 1 0.784314 rgBT /Ove	4.6	20
26	Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas. Future Oncology, 2021, 17, 1269-1283.	2.4	20
27	Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged ≥60 Years. Blood, 2019, 134, 237-237.	1.4	19
28	Combination of the Bruton's tyrosine kinase (BTK) inhibitor PCI-32765 with bendamustine (B)/rituximab (R) (BR) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase Ib/II study.. Journal of Clinical Oncology, 2012, 30, 6515-6515.	1.6	19
29	Outpatient administration of BEAM conditioning prior to autologous stem cell transplantation for lymphoma is safe, feasible, and cost-effective. Cancer Medicine, 2016, 5, 3059-3067.	2.8	18
30	Minimal Residual Disease (MRD) Assessment in the ECOG1411 Randomized Phase 2 Trial of Front-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma (MCL). Blood, 2019, 134, 751-751.	1.4	18
31	POLARIX: A phase 3 study of polatuzumab vedotin (pola) plus R-CHP versus R-CHOP in patients (pts) with untreated DLBCL.. Journal of Clinical Oncology, 2019, 37, TPS7571-TPS7571.	1.6	17
32	Patterns and Timing of Failure for Diffuse Large B-Cell Lymphoma After Initial Therapy in a Cohort Who Underwent Autologous Bone Marrow Transplantation for Relapse. International Journal of Radiation Oncology Biology Physics, 2016, 96, 372-378.	0.8	15
33	Updated Results from a Phase II Study of Galiximab (Anti-CD80) in Combination with Rituximab for Relapsed or Refractory, Follicular NHL.. Blood, 2005, 106, 2435-2435.	1.4	14
34	PET-Directed Therapy for Patients with Limited-Stage Diffuse Large B-Cell Lymphoma - Results of Intergroup Nctn Study S1001. Blood, 2019, 134, 349-349.	1.4	13
35	Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHOLON-1 study. Hematological Oncology, 2021, 39, 185-195.	1.7	12
36	Frontline Brentuximab Vedotin As Monotherapy or in Combination for Older Hodgkin Lymphoma Patients. Blood, 2020, 136, 18-19.	1.4	12

#	ARTICLE	IF	CITATIONS
37	Rituximab maintenance in follicular lymphoma: PRIMA. <i>Lancet, The</i> , 2011, 377, 4-6.	13.7	11
38	A Phase 1/2 Study of Umbralisib Ublituximab and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2019, 134, 360-360.	1.4	11
39	State of the Science: Cancer Complementary and Alternative Medicine Therapeutics Research NCI Strategic Workshop Highlights of Discussion Report. <i>Journal of the National Cancer Institute Monographs</i> , 2017, 2017, .	2.1	10
40	Hemophagocytic lymphohistiocytosis masquerading as progressive chronic lymphocytic leukemia. <i>Leukemia Research Reports</i> , 2013, 2, 4-6.	0.4	9
41	Vulnerable Elders Survey-13 (VES-13) Predicts 1-Year Mortality Risk in Newly Diagnosed Non-Hodgkin Lymphoma (NHL). <i>Blood</i> , 2019, 134, 69-69.	1.4	9
42	Phase 2 trial of GS-9973, a selective syk inhibitor, and idelalisib (idela) in chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL).. <i>Journal of Clinical Oncology</i> , 2014, 32, 7059-7059.	1.6	9
43	SWOG S1826: A Phase III, Randomized Study of Nivolumab Plus AVD or Brentuximab Vedotin Plus AVD in Patients with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2020, 136, 23-24.	1.4	9
44	First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7503-7503.	1.6	9
45	Diffuse Large B-Cell NHL. , 2006, 131, 121-140.		6
46	A Phase 1/2 Study of Umbralisib, Ublituximab, and Venetoclax (U2-Ven) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL). <i>Blood</i> , 2020, 136, 41-42.	1.4	6
47	Consolidative Radioimmunotherapy After Chemoimmunotherapy in Patients With Histologic Transformation of Indolent Non-Hodgkin Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 322-328.e2.	0.4	5
48	Patients with diffuse large B-cell lymphoma requiring urgent treatment: its implication on trial design and interpretation. <i>Leukemia and Lymphoma</i> , 2019, 60, 3569-3572.	1.3	4
49	Potential Factors That Impact Lenalidomide/R-CHOP Efficacy in Previously Untreated Diffuse Large B-Cell Lymphoma in the ROBUST and ECOG-ACRIN 1412 Studies. <i>Blood</i> , 2019, 134, 4092-4092.	1.4	4
50	Frontline Bendamustine and Rituximab in Extranodal Marginal Zone Lymphoma: An International Analysis. <i>Blood</i> , 2020, 136, 2-3.	1.4	4
51	A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 5-6.	1.4	4
52	U.S. Intergroup phase II trial (SWOG 1108) of alisertib, an investigational aurora A kinase (AAK) inhibitor, in patients with peripheral T-cell lymphoma (PTCL; NCT01466881).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8523-8523.	1.6	4
53	Phase 3 study of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A+AVD) versus doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as front-line treatment for advanced classical Hodgkin lymphoma (HL): Echelon-1 study.. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS8613-TPS8613.	1.6	4
54	Brentuximab vedotin (BV) plus chemotherapy in patients with newly diagnosed advanced stage Hodgkin lymphoma (HL): North American results.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7541-7541.	1.6	4

#	ARTICLE	IF	CITATIONS
55	Long-term follow-up of brentuximab vedotin ± dacarbazine as first line therapy in elderly patients with Hodgkin lymphoma.. Journal of Clinical Oncology, 2018, 36, 7542-7542.	1.6	4
56	An intergroup collaboration for advanced stage classical Hodgkin lymphoma (cHL) in adolescents and young adults (AYA): SWOG S1826.. Journal of Clinical Oncology, 2020, 38, TPS8067-TPS8067.	1.6	4
57	Utility and Patterns of Use of PET/CT and Bone Marrow Biopsy for Staging in Non-Hodgkin Lymphoma in the Clinical Setting: A Retrospective Analysis Using the LEO Database. Blood, 2019, 134, 1610-1610.	1.4	3
58	Brentuximab Vedotin Monotherapy and in Combination with Dacarbazine in Frontline Treatment of Hodgkin Lymphoma in Patients Aged 60 Years and Above: Interim Results of a Phase 2 Study. Blood, 2014, 124, 294-294.	1.4	3
59	A phase 3 study comparing polatuzumab vedotin plus R-CHP versus R-CHOP in patients with DLBCL (POLARIX).. Journal of Clinical Oncology, 2018, 36, TPS7589-TPS7589.	1.6	3
60	Frontline brentuximab vedotin as monotherapy or in combination for older Hodgkin lymphoma patients.. Journal of Clinical Oncology, 2020, 38, 8032-8032.	1.6	3
61	Prognostication for Advanced Stage Hodgkin Lymphoma (HL) in the Modern Era: A Project from the Hodgkin Lymphoma International Study for Individual Care (HoLISTIC) Consortium. Blood, 2020, 136, 16-18.	1.4	2
62	Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation,. Blood, 2011, 118, 3295-3295.	1.4	2
63	Phase I Study of Eltrombopag for Promoting Thrombopoiesis in Patients Undergoing Stem Cell Transplantation After Total Body Irradiation. Blood, 2012, 120, 219-219.	1.4	2
64	Lifelong disease burden of chemotherapy in Hodgkin lymphoma (HL): A simulation study from the St. Jude Lifetime (SJLIFE) Cohort and HL International Study for Individual Care (HoLISTIC).. Journal of Clinical Oncology, 2020, 38, 12068-12068.	1.6	2
65	Toward a Cure for Follicular Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, xiii-xiv.	2.2	2
66	Toxicity patterns of novel PI3K combinations in patients with non-Hodgkin lymphoma. Leukemia and Lymphoma, 2021, 62, 598-605.	1.3	1
67	A Pilot Study of Brentuximab Vedotin Combined with AVD Chemotherapy and Radiotherapy in Patients with Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma. Blood, 2019, 134, 2834-2834.	1.4	1
68	Treatment with Full Chemotherapy Regimens in Older Adults with Hodgkin Lymphoma Improves 3-Year Overall Survival, but Less Than Half Receive Full Regimens. Blood, 2019, 134, 1563-1563.	1.4	1
69	High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender. Blood, 2014, 124, 3046-3046.	1.4	1
70	Outpatient Administration of High Dose BEAM Chemotherapy As Conditioning for Autologous Stem Cell Transplantation for Lymphoma Results in Fewer Infectious Complications and Improved Survival. Blood, 2014, 124, 3984-3984.	1.4	1
71	Prevalence and clinical correlates of vulnerable status using the Vulnerable Elders Survey 13 (VES-13) in newly diagnosed adult non-Hodgkin lymphoma (NHL) patients: A LEO cross-sectional analysis.. Journal of Clinical Oncology, 2018, 36, 10042-10042.	1.6	1
72	Central line-associated complications during treatment with DA-R-EPOCH therapy for NHL.. Journal of Clinical Oncology, 2017, 35, 7543-7543.	1.6	1

#	ARTICLE	IF	CITATIONS
73	The Hodgkin lymphoma international study for individual care (HoLISTIC): Enhancing decision making in pediatric and adult Hodgkin lymphoma (HL).. Journal of Clinical Oncology, 2020, 38, e20019-e20019.	1.6	1
74	Relevance of bone marrow biopsies for response assessment in NCTN follicular lymphoma clinical trials.. Journal of Clinical Oncology, 2020, 38, 8038-8038.	1.6	1
75	Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis. Blood, 2020, 136, 35-36.	1.4	1
76	Arrhythmia Burden in Patients with Indolent Lymphoma. Blood, 2020, 136, 6-7.	1.4	1
77	Brentuximab vedotin for the treatment of Hodgkinâ€™s and non-Hodgkinâ€™s lymphoma. Expert Opinion on Orphan Drugs, 2015, 3, 609-618.	0.8	0
78	Key Clinical and Translational Research Questions to Address Unmet Needs in Mantle Cell Lymphoma. Hematology/Oncology Clinics of North America, 2020, 34, 983-996.	2.2	0
79	The Novel Proteasome Inhibitor Carfilzomib Interacts Synergistically with HDAC Inhibitors in ABC- and GC-DLBCL Cells Both in Vitro and In Vivo through Mechanisms Involving JNK Activation, NF-Î²B Inactivation, and DNA Damage... Blood, 2009, 114, 1688-1688.	1.4	0
80	Phase I/II study of investigational agent MLN8237 (alisertib) plus rituximab with or without vincristine in patients (pts) with relapsed/refractory (rel/ref) aggressive diffuse large B-cell lymphoma (DLBCL)/transformed follicular lymphoma (TFL).. Journal of Clinical Oncology, 2012, 30, TPS8109-TPS8109.	1.6	0
81	Fostamatinib Inhibits BCR Signaling, and Reduces Tumor Cell Activation and Proliferation in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia.. Blood, 2012, 120, 2882-2882.	1.4	0
82	Differences in disease characteristics, treatment patterns, and outcomes between men (M) and women (W) with follicular lymphoma (FL): Prospective evaluation of 2,650 U.S. patients (pts).. Journal of Clinical Oncology, 2014, 32, 8550-8550.	1.6	0
83	Late Relapses Following High Dose Chemotherapy and Autologous Stem Cell Transplant in Patients with Diffuse Large B Cell Lymphoma in the Rituximab Era. Blood, 2014, 124, 3999-3999.	1.4	0
84	Consolidative Radioimmunotherapy after Chemoimmunotherapy in Patients with Histologic Transformation of Indolent Lymphoma. Blood, 2014, 124, 1746-1746.	1.4	0
85	Enrollment of high-risk patients with diffuse large B-cell lymphoma in clinical trials.. Journal of Clinical Oncology, 2017, 35, 6536-6536.	1.6	0
86	ILyAD (Indolent Lymphoma and Vitamin D): A phase III double blind, prospective randomized trial to evaluate the supplemental effect of vitamin D on progression-free survival in patients with low tumor-burden indolent non-Hodgkin lymphoma treated with rituximab therapy.. Journal of Clinical Oncology, 2018, 36, TPS7587-TPS7587.	1.6	0
87	Outcomes of lenalidomide in diffuse large B-cell (DLBCL) and high-grade NHL (HGBCL): A single-center retrospective analysis.. Journal of Clinical Oncology, 2019, 37, 7547-7547.	1.6	0
88	The role of frailty and comorbidity in treatment (tx) of elderly patients with Hodgkin lymphoma (HL).. Journal of Clinical Oncology, 2019, 37, e19011-e19011.	1.6	0
89	High risk patients with diffuse large B cell lymphoma are not enrolled on clinical trials.. Journal of Clinical Oncology, 2019, 37, e19058-e19058.	1.6	0
90	Indolent Lymphoma and Vitamin D (ILyAD): A Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Supplemental Effect of Vitamin D on Event-Free Survival in Patients with Low Tumor Burden Indolent Non-Hodgkin Lymphoma Treated with Rituximab. Blood, 2019, 134, 4008-4008.	1.4	0

#	ARTICLE	IF	CITATIONS
91	Intraclonal Heterogeneity Caused By Activation-Induced Cytidine Deaminase Is Not a Prognostic Biomarker in Untreated Advanced Stage Follicular Lymphoma: An Analysis of SWOG S0016. <i>Blood</i> , 2019, 134, 2771-2771.	1.4	0
92	Phase II Study of Acalabrutinib and High-Frequency Low-Dose Subcutaneous Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , 2021, 138, 2640-2640.	1.4	0
93	Patient and Disease Factors Predict Risk of 1-Year Mortality Among Older Adults Who Receive Intensive Chemotherapy for Hodgkin Lymphoma (HL). <i>Blood</i> , 2020, 136, 6-7.	1.4	0
94	Evaluation of Activation of a NCI National Clinical Trials Network (NCTN) Study S1826 for Hodgkin Lymphoma (HL) at Children's Oncology Group (COG) Institutions. <i>Blood</i> , 2020, 136, 20-20.	1.4	0
95	Local Review Versus (vs) Central Review of Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) in Diffuse Large B-Cell Lymphoma (DLBCL): Results from the CALGB 50303 Trial [Alliance]. <i>Blood</i> , 2020, 136, 50-50.	1.4	0
96	Alliance A059102: A randomized phase II U.S. intergroup study of CHO(E)P versus CC-486-CHO(E)P versus duvelisib-CHO(E)P in previously untreated, CD30-negative, peripheral T-cell lymphomas.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7593-TPS7593.	1.6	0
97	Therapy for patients with POD24 follicular lymphoma: Treatment patterns and outcomes from the Lymphoma Epidemiology of Outcomes (LEO) Consortium.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7573-7573.	1.6	0
98	A novel microbial-derived peptide therapeutic vaccine (EO2463) as monotherapy and in combination with lenalidomide and rituximab, for treatment of patients with indolent non-Hodgkin lymphoma (SIDNEY).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS7586-TPS7586.	1.6	0